List of Excipients in Branded Drug ELYXYB - CELECOXIB

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BioDelivery Sciences International Inc	ELYXYB - CELECOXIB	celecoxib	59385-055	ACESULFAME POTASSIUM
BioDelivery Sciences International Inc	ELYXYB - CELECOXIB	celecoxib	59385-055	ALCOHOL
BioDelivery Sciences International Inc	ELYXYB - CELECOXIB	celecoxib	59385-055	AMMONIUM GLYCYRRHIZATE
BioDelivery Sciences International Inc	ELYXYB - CELECOXIB	celecoxib	59385-055	BANANA
BioDelivery Sciences International Inc	ELYXYB - CELECOXIB	celecoxib	59385-055	GLYCERIN
BioDelivery Sciences International Inc	ELYXYB - CELECOXIB	celecoxib	59385-055	GLYCERYL MONOCAPRYLATE

ELYXYB (Celecoxib) Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

ELYXYB is a differentiated celecoxib product built around rapid oral delivery rather than a new active ingredient. Its commercial value depends on the formulation's ability to solubilize poorly water-soluble celecoxib, deliver a 120 mg migraine dose in a small liquid volume, and avoid the swallowing and gastrointestinal disintegration steps associated with conventional capsules. The main opportunities are generic or 505(b)(2) liquid development, lifecycle reformulation, contract manufacturing, excipient supply, and migraine-focused distribution.

What is ELYXYB and how does it differ from celecoxib capsules?

ELYXYB is an oral solution containing celecoxib at 25 mg/mL. The approved adult dose for the acute treatment of migraine with or without aura is 120 mg, administered as 4.8 mL. It is not approved for preventive migraine treatment or for general chronic pain indications. The product was approved by the FDA in May 2020 through the 505(b)(2) pathway. [1]

Attribute	ELYXYB	Conventional celecoxib capsule
Active ingredient	Celecoxib	Celecoxib
Dosage form	Oral solution	Hard gelatin capsule
Strength	25 mg/mL	Commonly 50, 100, 200 and 400 mg capsules
Approved use	Acute migraine in adults	Osteoarthritis, rheumatoid arthritis, acute pain and other approved indications
Approved migraine dose	120 mg, or 4.8 mL	Not the same FDA-approved liquid migraine product
Development pathway	505(b)(2) NDA	Conventional drug product pathway
Formulation objective	Rapid solubilized delivery	Solid oral dose disintegration and dissolution
Key commercial distinction	Small-volume liquid for acute migraine	Familiar capsule form with broader historical use

The product's differentiation comes from the delivery system, not from a new molecular entity. Celecoxib was already an established cyclooxygenase-2 selective NSAID, marketed for years before ELYXYB approval.

What excipients are used in ELYXYB?

ELYXYB uses a solubilization system based on sulfobutylether-beta-cyclodextrin sodium, supported by pH adjustment, surfactant activity and liquid-product preservation. The FDA prescribing information identifies the inactive ingredients as sulfobutylether-beta-cyclodextrin sodium, meglumine, polysorbate 80, benzyl alcohol, citric acid, sodium citrate and water. [1]

Excipient	Likely formulation function	Commercial and technical relevance
Sulfobutylether-beta-cyclodextrin sodium	Complexing agent and solubilizer	Central to maintaining celecoxib in a concentrated aqueous solution
Meglumine	pH modifier and cosolubilizing counterion	Can improve apparent solubility and support formulation pH
Polysorbate 80	Surfactant and wetting aid	Supports dispersion and reduces precipitation risk
Benzyl alcohol	Preservative or antimicrobial protection	Requires control of concentration, labeling and patient-population restrictions
Citric acid	Acidifying agent and buffer component	Controls pH and formulation stability
Sodium citrate	Buffer component	Helps maintain pH during storage
Purified water	Vehicle	Determines concentration, microbial control and packaging requirements

Why is sulfobutylether-beta-cyclodextrin important?

Celecoxib has low aqueous solubility. Cyclodextrins improve apparent solubility by forming reversible inclusion complexes in which hydrophobic portions of the drug associate with the cyclodextrin cavity while the exterior remains compatible with water.

Sulfobutylether-beta-cyclodextrin sodium, commonly known as SBECD, is used in several approved parenteral and oral drug products. It is more suitable for pharmaceutical solubilization than unmodified beta-cyclodextrin because its sulfobutyl substituents improve aqueous solubility.

For ELYXYB, SBECD has four strategic functions:

1. It enables a 25 mg/mL celecoxib liquid.
2. It reduces dependence on organic cosolvents.
3. It supports a small administration volume.
4. It creates a formulation barrier that may be more difficult to reproduce than a conventional celecoxib capsule.

The excipient itself is not necessarily a standalone exclusivity barrier. The commercial barrier lies in the combination of cyclodextrin grade, celecoxib-to-excipient ratio, pH, surfactant concentration, precipitation control, packaging and manufacturing process.

What role do meglumine and polysorbate 80 play?

Meglumine can improve solubilization through pH modification and ion-pair or salt-related effects. Its value is formulation-specific because increasing pH can improve celecoxib solubility while affecting chemical stability, taste, tolerability and precipitation during dilution.

Polysorbate 80 improves wetting and helps maintain a uniform liquid system. It can also reduce interfacial instability during manufacturing and storage. Its use creates standard quality risks, including peroxide formation, oxidation-sensitive drug interactions and lot-to-lot variability.

Why does the preservative strategy matter?

If benzyl alcohol is present, its concentration and packaging configuration affect regulatory review and commercial positioning. Benzyl alcohol is not suitable for all populations, particularly neonates and certain pediatric populations. ELYXYB is approved for adults, limiting the immediate clinical impact of this issue, but it remains relevant for future pediatric development or broader migraine labeling.

A single-dose package can reduce microbial risk and simplify patient handling. It also limits the need for repeated opening and reduces the formulation burden associated with multidose preservation. The tradeoff is higher packaging cost and more waste per administered dose.

How does the ELYXYB formulation support migraine treatment?

ELYXYB is designed for acute treatment, where patients may value rapid administration and ease of swallowing. A liquid formulation can be useful for patients experiencing nausea, dysphagia or difficulty taking tablets during a migraine episode.

The formulation does not eliminate the pharmacologic limitations of celecoxib. It remains subject to the NSAID class warnings for cardiovascular and gastrointestinal risk, and the product label carries contraindications and precautions applicable to celecoxib. [1]

Its clinical positioning is strongest when the formulation advantage is material:

• Patients who cannot comfortably swallow capsules.
• Patients who prefer a liquid for acute migraine.
• Situations requiring a compact, premeasured dose.
• Patients seeking an alternative to triptans or CGRP-pathway drugs.
• Prescribers who want a nontriptan acute treatment with a familiar NSAID mechanism.

The liquid format is less compelling for patients who already use inexpensive generic celecoxib capsules or over-the-counter NSAIDs successfully.

What commercial opportunities exist for ELYXYB excipients?

Which excipients offer the largest supply opportunity?

SBECD is the most strategically important excipient because it is required at a comparatively high level to maintain celecoxib solubility. The opportunity is strongest for suppliers that can provide:

• Pharmaceutical-grade SBECD with consistent substitution levels.
• Low impurity and low endotoxin profiles.
• Reliable global supply.
• Regulatory documentation for U.S., European and other markets.
• Technical support for scale-up and precipitation control.

Polysorbate 80, meglumine, citrate buffers and purified water are more readily sourced. They still create quality and supply-chain requirements, but they are less likely to determine product differentiation.

Can excipient suppliers obtain meaningful patent protection?

Excipient suppliers generally obtain commercial protection through manufacturing know-how, specifications, quality documentation and supply agreements rather than through a single product-specific patent. A supplier may create switching costs through:

• Drug-master-file support.
• Locked-in grade specifications.
• Process validation.
• Stability data.
• Regulatory change-control commitments.
• Long-term supply contracts.

For a follow-on ELYXYB product, the drug manufacturer may qualify more than one SBECD supplier, but changing grade or source can trigger comparability and stability work. That creates a practical advantage for the incumbent supplier even when the excipient is not legally exclusive.

What formulation patents protect ELYXYB?

The relevant protection is expected to center on the liquid celecoxib formulation, solubilization system, dosage form and use in acute migraine rather than on the celecoxib molecule itself. Celecoxib's core composition-of-matter protection expired before ELYXYB approval.

A complete freedom-to-operate review should examine:

• U.S. patents listed in the FDA Orange Book for the ELYXYB NDA.
• Patents covering liquid celecoxib compositions.
• Claims directed to cyclodextrin-containing formulations.
• Claims covering celecoxib concentration and administration volume.
• Method-of-use claims for acute migraine.
• Continuations, divisionals and terminal disclaimers.
• Patent-family members in Europe, Canada, Japan and other commercial markets.

The practical risk is not limited to an exact ingredient list. A patent may cover a broader formulation range or a functional limitation such as maintaining celecoxib in solution, achieving a defined dissolution profile or reducing precipitation after administration.

What is the Orange Book status of ELYXYB?

ELYXYB is an approved NDA product and its listed patents, if any remain active, should be assessed in the current FDA Orange Book. The product also received the standard three-year exclusivity associated with a qualifying new clinical investigation supporting a change in dosage form or indication. That regulatory exclusivity period ran from the May 2020 approval and would not block an ANDA indefinitely. [1, 2]

A generic applicant must distinguish between:

• FDA regulatory exclusivity, which can expire without patent expiration.
• Orange Book-listed patents, which can delay approval or trigger litigation.
• Unlisted formulation know-how, which may still create development risk.
• Method-of-use claims, which may be addressed through a section viii statement or labeling carve-out if legally available.

When did ELYXYB lose regulatory exclusivity?

The three-year exclusivity associated with the 2020 approval would have expired in 2023. That timing opened the possibility of ANDA or 505(b)(2) competition, subject to any remaining listed patents and the applicant's legal certifications.

ELYXYB did not receive new chemical entity exclusivity because celecoxib was already an approved active ingredient. It also is not a biologic and therefore has no biosimilar pathway. The relevant competitive routes are generic drug applications and 505(b)(2) applications.

What generic entry risks exist for ELYXYB?

Generic entry is technically more difficult than copying a conventional celecoxib capsule. An applicant must reproduce a stable, concentrated aqueous solution with acceptable:

• Assay and content uniformity.
• pH control.
• Viscosity and appearance.
• Microbial quality.
• Preservative performance, if applicable.
• Cyclodextrin-drug complexation.
• Stability under temperature and light stress.
• Container-closure compatibility.
• Taste and patient acceptability.

The FDA may require comparative analytical data and, depending on the regulatory route, bioequivalence evidence. The applicant may also pursue a 505(b)(2) strategy if the reference product's formulation or clinical use creates a regulatory advantage.

What generic launch scenarios are plausible?

Scenario	Likely competitive effect
One approved liquid generic	Moderate price erosion; retains liquid-specific niche
Multiple ANDA products	Significant price pressure and formulary substitution
505(b)(2) liquid with different excipients	Differentiated labeling or packaging, but potentially higher development cost
Generic capsule substitution	Large volume pressure if payers treat the products as therapeutically interchangeable
Compounded liquid celecoxib	Limited commercial impact because of quality, stability and reimbursement constraints
New rapid-delivery celecoxib product	Could bypass direct formulation copying and compete on administration convenience

The most credible first entrants would likely be companies with existing NSAID portfolios, oral-liquid manufacturing capacity or experience with cyclodextrin-based solubilization.

How strong is the ELYXYB patent estate?

The patent estate is likely moderate rather than foundational. Celecoxib itself is off-patent, and the commercial differentiation depends on formulation and indication claims. Formulation patents can be valuable when they cover a narrow but difficult-to-design-around composition, but their strength depends on claim scope and reproducibility.

Strength factors

• High drug loading in an aqueous oral solution.
• Use of SBECD with defined celecoxib concentration.
• A specific 4.8 mL, 120 mg administration format.
• Claims linking the formulation to acute migraine treatment.
• Manufacturing controls needed to prevent precipitation.
• Potential separation between composition claims and method-of-use claims.

Weakness factors

• Broad use of known excipients.
• Availability of alternative cyclodextrins or cosolvent systems.
• Ability to change buffer, surfactant or preservative levels.
• Difficulty proving infringement of functional formulation claims.
• Availability of capsule-based celecoxib alternatives.
• Limited regulatory exclusivity after 2023.

The main barrier is likely formulation development and regulatory execution, not long-term molecular exclusivity.

Which companies could challenge ELYXYB?

Potential challengers include generic manufacturers with:

• Approved oral-liquid facilities.
• Established celecoxib or NSAID portfolios.
• Experience with 505(b)(2) products.
• SBECD sourcing and analytical capability.
• Migraine-focused commercial infrastructure.

The most relevant competitive groups are large generic companies, specialty pharmaceutical firms and contract development and manufacturing organizations. A challenger does not need to duplicate ELYXYB exactly if it can develop a clinically and regulatorily acceptable liquid celecoxib product through an alternative pathway.

A public assessment of actual Paragraph IV filings, ANDA applicants and settlement agreements requires the current FDA and court records. The regulatory risk should therefore be analyzed product by product rather than inferred from the existence of generic celecoxib capsules.

What litigation and settlement issues affect ELYXYB?

The central litigation issues would be:

1. Whether an ANDA applicant files a Paragraph IV certification against listed formulation or method-of-use patents.
2. Whether the NDA holder files suit within the statutory 45-day period.
3. Whether a 30-month stay applies.
4. Whether the applicant uses a section viii statement to omit a patented migraine indication.
5. Whether the parties settle with an authorized generic, license or agreed launch date.
6. Whether a later patent or continuation creates a second litigation cycle.

A settlement could produce an authorized generic launch, a delayed generic entry date or a license limited to certain indications and territories. Because ELYXYB is a dosage-form product with a relatively narrow indication, litigation economics may be less attractive than litigation involving a blockbuster chronic-use product.

What are the geographic opportunities for ELYXYB-style products?

The United States is the clearest market for a liquid celecoxib migraine product because ELYXYB has FDA approval and a defined regulatory reference. Other markets may offer opportunities for:

• Acute migraine liquids.
• Pediatric or adolescent formulations, subject to safety and regulatory requirements.
• Unit-dose sachets or stick packs.
• Hospital and urgent-care supply.
• Preservative-free presentations.
• Lower-volume products for patients with swallowing difficulty.
• Combination migraine packs with antiemetic therapy.

International development would require separate assessment of celecoxib labeling, migraine treatment standards, excipient acceptability, packaging rules and local patent rights. SBECD is generally familiar to regulators, but the commercial value of an ELYXYB-style product will depend on reimbursement and the availability of low-cost celecoxib capsules.

What manufacturing and intellectual-property barriers matter most?

The highest-value manufacturing know-how is likely to involve:

• Achieving complete celecoxib solubilization.
• Controlling complex formation with SBECD.
• Preventing precipitation during storage and dosing.
• Maintaining acceptable taste and mouthfeel.
• Controlling surfactant and preservative degradation.
• Filling a low-volume dose accurately.
• Managing extractables and leachables from the container.
• Establishing stability after opening or dose withdrawal.

Packaging is a potentially meaningful commercial differentiator. Single-dose bottles improve dose accuracy and microbial control but increase packaging and logistics costs. Unit-dose oral syringes, ampoules or stick packs could reduce administration errors and create new patentable combinations of container and formulation.

How does ELYXYB compare with other acute migraine drugs?

Product class	Main advantage	Main limitation relative to ELYXYB
Triptans	Established efficacy and broad availability	Vasoconstriction-related restrictions and oral administration limitations
Gepants	Nonvasoconstrictive mechanism	Higher cost and newer competitive field
Dihydroergotamine products	Alternative mechanism and delivery routes	Tolerability and administration complexity
NSAID capsules	Low cost and broad familiarity	Swallowing, dissolution and generic substitution
ELYXYB	Liquid celecoxib with small-volume dosing	Narrow indication, NSAID safety risks and potentially high price

ELYXYB's strongest competitive position is as a formulation-driven alternative for acute migraine patients who need or prefer liquid dosing. Its weakest position is against low-cost generic NSAIDs when price is the primary prescribing factor.

What revenue exposure and licensing opportunities exist?

Revenue exposure depends on the product's ability to maintain a premium over generic celecoxib while expanding migraine treatment access. The principal commercial risks are generic entry, payer rejection, low repeat use and competition from CGRP antagonists.

Licensing opportunities include:

• Regional commercialization rights.
• Authorized-generic arrangements.
• Co-development of pediatric or preservative-free versions.
• SBECD supply agreements.
• Contract formulation and fill-finish services.
• Acquisition of formulation patents or know-how.
• Migraine portfolio combinations with antiemetics or other acute therapies.

A licensee is more likely to pay for an ELYXYB-style asset when it receives protected geography, manufacturing exclusivity, a differentiated package or access to a broader migraine portfolio. A simple liquid celecoxib license without patent or supply-chain control has limited negotiating leverage.

Key Takeaways

• ELYXYB is a 25 mg/mL celecoxib oral solution approved for acute migraine in adults.
• SBECD is the central excipient because it enables high-concentration aqueous solubilization.
• Meglumine, polysorbate 80 and citrate buffers support pH control, wetting and formulation stability.
• The product's competitive advantage is administration convenience, not a new active ingredient.
• Regulatory exclusivity from the 2020 approval expired in 2023, leaving patent and formulation barriers as the main defenses.
• Generic development is feasible but requires substantial work on solubility, precipitation, stability, microbial quality and packaging.
• The most attractive commercial opportunities are liquid-generic development, 505(b)(2) reformulation, unit-dose packaging and pharmaceutical-grade SBECD supply.
• The patent estate is likely formulation- and use-based, making claim scope and design-around analysis more important than celecoxib molecular protection.
• ELYXYB has no biosimilar risk because it is a small-molecule drug, not a biologic.
• Commercial upside is constrained by inexpensive generic celecoxib capsules, NSAID safety warnings and competition from triptans and CGRP therapies.

FAQs About ELYXYB Celecoxib Formulation and Commercialization

Can ELYXYB be reformulated without sulfobutylether-beta-cyclodextrin?

Yes. A developer could evaluate alternative cyclodextrins, cosolvents, surfactant systems, lipid vehicles or pH-based approaches. The alternative must maintain solubility, stability, tolerability and regulatory performance.

Is ELYXYB eligible for a biosimilar application?

No. Celecoxib is a chemically synthesized small molecule. Follow-on products would use an ANDA, 505(b)(2) NDA or another applicable small-molecule pathway, not a biosimilar application.

Could a generic ELYXYB omit the migraine indication?

Potentially. A section viii statement may allow an applicant to carve out a patented method of use if the remaining labeling and product design satisfy FDA requirements. The legal feasibility depends on the specific Orange Book listing and claim scope.

Does a liquid celecoxib product have a major taste-masking problem?

It can. Celecoxib and concentrated solubilization systems may produce bitterness, astringency or an undesirable mouthfeel. Taste acceptability can affect adherence, especially when a product competes with capsules that avoid oral exposure to the dissolved drug.

Is SBECD a likely supply-chain bottleneck?

SBECD is commercially available, but supplier qualification, grade consistency and regulatory documentation can limit rapid switching. A manufacturer with validated SBECD sourcing has an advantage during scale-up and post-approval change management.

References

1. U.S. Food and Drug Administration. (2023). ELYXYB (celecoxib) oral solution prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2020). Approval package for ELYXYB (NDA 211816). Drugs@FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2024). ANDA, 505(b)(2), and patent certification procedures. FDA Center for Drug Evaluation and Research.

5. National Library of Medicine. (2024). DailyMed: ELYXYB- celecoxib solution. U.S. National Library of Medicine.